<unk> , marketed under the brand name Libmeldy, is a gene therapy treatment for metachromatic leukodystrophy (MLD) developed by Orchard Therapeutics. It contains an autologous CD34⁺ cell enriched population that contains haematopoietic stem and progenitor cells transduced using a lentiviral vector encoding the human arylsulfatase A (ARSA) gene.
Atidarsagene autotemcel
Bald's eyesalve
Eyepatch
SpyCatcher
Eyeborg
InBev-Baillet Latour Fund
Zebra print ribbon
Hobcart